GSK1904529A - CAS:1089283-49-7

您当前的位置：

GSK1904529A

目录号 : KM6340 CAS No. : 1089283-49-7 纯度 : 98%

Data Sheet SDS 产品使用指南

GSK1904529A 是一种有效的，选择性的，具有口服活性和 ATP 竞争性的胰岛素样生长因子 1 受体 (IGF-1R) 和胰岛素受体 (IR) 抑制剂，IC₅₀ 值分别为 27 和 25 nM。GSK1904529A 在其他 45 种丝氨酸/苏氨酸和酪氨酸激酶中显示出较弱的活性 (IC₅₀>1 μM)。GSK1904529A 具有抗肿瘤活性。

规格	价格	是否有货
10mg		In-stock
50mg		In-stock
100mg		In-stock
200mg	询价	In-stock
500mg	询价	In-stock

加入购物车大包装询价

Other Forms of Rapamycin:

Dydrogesterone-D6 In-stock
Prostaglandin E1-d4 In-stock
Norcholic acid In-stock
Dicyclohexyl phthalate-3,4,5,6-d4 In-stock
Mebhydrolin napadisylate In-stock

KKL Med 的所有产品和服务仅用于科学研究，不能被用于人体，兽医，我们也不向个人提供产品和服务。

生物活性

GSK1904529A is a potent, selective, orally active, and ATP-competitive inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), with IC₅₀s of 27 and 25 nM, respectively. GSK1904529A shows poor activity (IC₅₀>1 μM) in 45 other serine/threonine and tyrosine kinases. GSK1904529A exhibits anti-tumor activity.

IC₅₀&Target

IC50: 27 nM (IGF-1R), 25 nM (IR)

体外研究

GSK1904529A displays high affinities for IGF-1R and IR, with K_is of 1.6 and 1.3 nM, respectively.
GSK1904529A (72 h) inhibits tumor cells proliferation with IC₅₀s ranges from 35 nM to >30 μM, and Ewing's sarcoma and multiple myeloma cell lines are greatest sensitive.
GSK1904529A (0.03-3 μM; 24 and 48 h) arrests cells at the G1 phase of the cell cycle.
GSK1904529A (2 h) inhibits phosphorylation of IGF-IR and IR with IC₅₀s of 22 and 19 nM in NIH-3T3/LISN and NIH-3T3-hIR cells, respectively.
GSK1904529A (0.01-3 μM; 4 h) blocks the major downstream signal transduction pathways mediated by IGF-IR and IR in NIH-3T3/LISN and NIH-3T3-hIR cells.

Cell Cycle Analysis

Cell Line:	COLO 205, MCF-7, and NCI-H929 cells
Concentration:	0, 0.03, 0.1, 0.3, 1, 3 μM
Incubation Time:	24 and 48 hours
Result:	Increased the accumulation in G1 and decreased accumulation in S and G2-M phases of the cell cycle.

Western Blot Analysis

Cell Line:	NIH-3T3/LISN and NIH-3T3-hIR cells
Concentration:	0.01, 0.03, 0.1, 0.3, 1, 3 μM
Incubation Time:	4 hours
Result:	Inhibited the ligand-induced phosphorylation of IGF-IR and IR at concentrations >0.01 μM. Decreased the phosphorylation of AKT, IRS-1, and ERK.

体内研究

GSK1904529A (30 mg/kg; p.o. once or twice daily for 21 d) has antitumor activity in mice.
GSK1904529A (1-30 mg/kg; a single p.o.) decreases IGF-I-induced IGF-IR phosphorylation in a dose-dependent manner in mice.
GSK1904529A (30 mg/kg; p.o. once or twice daily for 21 d) has no significant alterations in the blood glucose levels in mice.

Animal Model:	Female athymic nu/nu CD-1 mice are bring NIH-3T3/LISN tumor
Dosage:	30 mg/kg
Administration:	P.o. once or twice daily for 21 d
Result:	Resulted in 56% (once daily) and 98% (twice daily) inhibition of tumor growth. No significant decrease in body weight on the once-daily schedule. Observed 11-13% of body weight loss, and recovered to near baseline 6 days after the cessation of treatment in twice-daily group.

分子式

C₅₁H₅₈F₂N₇O₅

分子量

851.96

CAS号

1089283-49-7

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 50 mg/mL (58.69 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.1738 mL	5.8688 mL	11.7376 mL
5 mM	0.2348 mL	1.1738 mL	2.3475 mL
10 mM	0.1174 mL	0.5869 mL	1.1738 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.75 mg/mL (3.23 mM); Clear solution

此方案可获得 ≥ 2.75 mg/mL (3.23 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 27.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

科研文献

纯度： 98%

Data Sheet

SDS

产品使用指南

暂无相关参考文献

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量

浓度

体积

分子量*

重置计算

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2

浓度

体积

浓度

体积

重置计算

动物实验计算换算器

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系客服为您提供正确的澄清溶液配方）

% DMSO

% Tween 80

% ddH₂O

% DMSO

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系客服）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

配置后的溶液总体积：

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

Other Forms of Rapamycin:

KKL 顾客使用本产品发表的 4 篇科研文献

The molarity calculator equation

The dilution calculator equation

动物实验计算换算器